Fludarabine
Disease Related To Hematopoietic Stem Cell Transplant
Explore 55 assets in Disease Related To Hematopoietic Stem Cell Transplant →Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
First Affiliated Hospital of Zhejiang University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07396480CT.gov Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial | — | Recruiting | — | — | — |
NCT05534620CT.gov Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics | — | Completed | — | — | — |
NCT05674539CT.gov Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome | — | Enrolling By Invitation | — | — | — |
NCT05436418CT.gov The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation | — | Recruiting | — | — | — |
NCT07232953CT.gov Safety and Efficacy of FT14 Conditioning for Allogeneic HSCT in Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT05583175CT.gov Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies | — | Unknown | — | — | — |
NCT05477589CT.gov Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML | — | Recruiting | — | — | — |
NCT04678401CT.gov IS-free Treg HaploHCT | — | Recruiting | — | — | — |
NCT04473911CT.gov Haplo Peripheral Blood Sct In GVHD Prevention | — | Completed | — | — | — |
NCT04220684CT.gov Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML | — | Completed | — | — | — |
Show 19 more trialsShow fewer
NCT03779854CT.gov Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant | — | Recruiting | — | — | — |
NCT03613532CT.gov Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN | — | Active Not Recruiting | — | — | — |
NCT03384225CT.gov CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AML | — | Unknown | — | — | — |
NCT03384212CT.gov CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML | — | Unknown | — | — | — |
NCT02653196CT.gov A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors | — | Terminated | — | — | — |
NCT02220985CT.gov Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD | — | Completed | — | — | — |
NCT02083250CT.gov Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant | — | Completed | — | — | — |
NCT01629511CT.gov Allogeneic Stem Cell Transplant for CLL | — | Terminated | — | — | — |
NCT01701986CT.gov Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma | — | Completed | — | — | — |
NCT01471067CT.gov Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies | — | Completed | — | — | — |
NCT01471444CT.gov Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | — | Completed | — | — | — |
NCT01208896CT.gov Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma | — | Completed | — | — | — |
NCT01010217CT.gov Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide | — | Completed | — | — | — |
NCT00990249CT.gov Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation | — | Completed | — | — | — |
NCT00972101CT.gov Infusion of Expanded Cord Blood T Cells | — | Withdrawn | — | — | — |
NCT00857389CT.gov Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies | — | Completed | — | — | — |
NCT00822770CT.gov Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin | — | Completed | — | — | — |
NCT00029393CT.gov Induction of Stable Chimerism for Sickle Cell Anemia | — | Completed | — | — | — |
NCT00029380CT.gov Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Disease Related To Hematopoietic Stem Cell Transplant
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fludarabine (this asset) | First Affiliated Hospital of Zhejiang University | P3 | BB · 69 |
| Busulfanum | Institute of Hematology & Blood Diseases Hospital, China | P3 | BBB |
| Cyclophosphamide | The First Affiliated Hospital of Soochow University | P3 | BBB |
| Nivestim | National Cancer Institute (NCI) | P2/3 | BBB |
| Decitabine | Chinese PLA General Hospital | P4 | BBB |
| Rituximab | M.D. Anderson Cancer Center | P2 | BBB |
| Tacrolimus | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | P3 | BB |
| Cyclosporin A | The First Affiliated Hospital of Soochow University | P4 | BB |
| Cytarabine | The First Affiliated Hospital of Soochow University | P3 | BB |
+42 more in the Disease Related To Hematopoietic Stem Cell Transplant cohort
Other indications for Fludarabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult T-Cell Leukemia/Lymphoma | — | P2 | BBB · 76 |
| Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) | — | P2 | BBB · 76 |
| Fanconi Anemia | — | P2/3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fludarabine in Disease Related To Hematopoietic Stem Cell Transplant. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fludarabine-disease-related-to-hematopoietic-stem-cell-transplant
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →